- Home
- CLLS vs PROF Comparison
CLLS vs PROF Comparison
Compare CLLS & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- PROF
- Stock Information
- Founded
- CLLS 1999
- PROF N/A
- Country
- CLLS France
- PROF Canada
- Employees
- CLLS N/A
- PROF N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- PROF Medical/Dental Instruments
- Sector
- CLLS Health Care
- PROF Health Care
- Exchange
- CLLS Nasdaq
- PROF Nasdaq
- Market Cap
- CLLS 299.0M
- PROF 134.3M
- IPO Year
- CLLS 2007
- PROF N/A
- Fundamental
- Price
- CLLS $2.99
- PROF $4.09
- Analyst Decision
- CLLS Buy
- PROF Strong Buy
- Analyst Count
- CLLS 1
- PROF 1
- Target Price
- CLLS $4.00
- PROF $11.00
- AVG Volume (30 Days)
- CLLS 77.9K
- PROF 181.3K
- Earning Date
- CLLS 11-03-2025
- PROF 11-06-2025
- Dividend Yield
- CLLS N/A
- PROF N/A
- EPS Growth
- CLLS N/A
- PROF N/A
- EPS
- CLLS N/A
- PROF N/A
- Revenue
- CLLS $63,438,000.00
- PROF $11,840,000.00
- Revenue This Year
- CLLS N/A
- PROF $60.07
- Revenue Next Year
- CLLS $66.76
- PROF $121.80
- P/E Ratio
- CLLS N/A
- PROF N/A
- Revenue Growth
- CLLS 223.09
- PROF 59.81
- 52 Week Low
- CLLS $1.10
- PROF $3.76
- 52 Week High
- CLLS $3.35
- PROF $9.17
- Technical
- Relative Strength Index (RSI)
- CLLS 61.44
- PROF 35.14
- Support Level
- CLLS $2.88
- PROF $3.76
- Resistance Level
- CLLS $3.35
- PROF $4.69
- Average True Range (ATR)
- CLLS 0.17
- PROF 0.19
- MACD
- CLLS 0.01
- PROF -0.00
- Stochastic Oscillator
- CLLS 57.65
- PROF 33.67
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.